萨库拉宁是一种新型抗炎剂,向TLR4-NF-κB信号通路
Jayasingha Arachchige Chathuranga Chanaka Jayasingha1, Kyoung Tae Lee2, Cheng-Yun Jin3
1Department of Marine Life Science, Jeju National University, Jeju, Republic of Korea.
Chemistry & biodiversity
|July 25, 2025
概括
萨库拉宁 (SKR) 通过抑制托尔类受体4 (TLR4) 途径有效降低炎症. 这种天然化合物通过阻断关键信号分子并改善细胞和斑马鱼模型的结果来治疗炎症性疾病具有前景.
科学领域:
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 萨库拉宁 (SKR) 具有已知的抗炎和抗氧化特性.
- SKR通过托尔类受体4 (TLR4) 信号调节炎症的精确分子机制尚未完全理解.
研究的目的:
- 为了研究SKR在脂聚糖 (LPS) 刺激的RAW 264.7巨和斑马鱼幼虫中的抗炎作用.
- 阐明SKR的作用背后的分子机制,重点关注TLR4-核因子-卡帕B (NF-κB) 信号通路.
主要方法:
- 在体外研究中,使用LPS刺激的RAW 264.7巨细胞来评估炎症标记物 (NO,PGE2,IL-12,TNF-α) 和基因/蛋白质表达 (NOS2,COX2).
- 使用斑马鱼幼虫的体内研究来评估SKR对LPS诱导的死亡率,心脏功能和免疫细胞透的系统性影响.
- 机械研究包括NF-κB核转位测定,分子对接和同位分析,以确定SKR与TLR4/MD2复合物的相互作用.
主要成果:
- SKR显著抑制了关键炎症媒介 (NO,PGE2,IL-12,TNF-α) 的产生,并降低了巨细胞中NOS2和COX2的表达.
- 在斑马鱼中,SKR降低了LPS诱导的死亡率,改善了心脏功能,降低了免疫细胞透.
- 发现SKR可以抑制NF-κB核转位,并直接结合TLR4/MD2复合体,破坏LPS-TLR4信号传输.
结论:
- 沙库拉宁是一种强大的TLR4介导炎症抑制剂,通过直接干扰TLR4/MD2复合体和下游NF-κB信号来起作用.
- 在体外和体内,SKR表现出显著的抗炎作用,这表明它对各种炎症疾病的治疗潜力.
- 需要进一步的研究来探索SKR的药理动力学,生物可用性和在慢性炎症条件中的疗效.
相关概念视频
NF-κB-dependent Signaling Pathway
7.9K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.9K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
235
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
235
The JAK-STAT Signaling Pathway
9.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.2K
Inflammatory Response
7.5K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
7.5K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
Inflammatory Bowel Disease IV: Pharmacological Management
193
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
193


